ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA

BACKGROUND: Recurrent glioblastoma has a poor median overall survival despite multimodal treatment. The use of pembrolizumab, an anti-PD-1 monoclonal antibody, demonstrates promise, including improved overall survival and increased immune response, when used in the neoadjuvant setting. METHODS: We e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Chow, Frances, Mochizuki, Aaron, Lee, Alexander, Galvez, Mildred, Orpilla, Joey, Everson, Richard, Liau, Linda, Cloughesy, Timothy, Prins, Robert
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Adult Clinical Trials–Immunologic
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847707/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.016
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky